Topic: pharmaceutical contract manufacturing
French CDMO Delpharm is planning a big expansion with a $274 million deal to pick up five sites from financially struggling Famar.
After manufacturing issues led ADMA Biologics to pull its primary immune deficiency disease drug Bivigam from the market, it's won a new FDA approval.
With two-thirds of its customers in the U.S., Sterling Pharma Solutions decided to buy a facility there.
Belgium-based Masthercell Global says it will build out a commercial-scale cell and gene manufacturing facility in its home country.
Novartis has reupped with Recro Pharma's CMO for production of two drugs, plus other news.
Thermo Fisher Scientific has completed its $7.2 billion acquisition of CDMO Patheon, weeks after Lonza completed its $5.5 billion buyout of Capsugel.
Boehringer Ingelheim saw a significant rise in sales in the first half of the year, in part from a healthy jump in its contract manufacturing operations.
Albany-New York based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot.
Charles River Laboratories has unloaded QS Pharma, a Philadelphia-area CDMO, months after picking it up as part of its $585 million buyout of WIL Research.
The massive CPhI show kicked off in Barcelona, Spain, on Tuesday with numbers that rival some small cities. An estimated 38,000 visitors from 150 countries swarmed through the facilities. They came to meet, look and listen to about 2,500 exhibitors.